



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke et al.

Application No.: 09/918,359

Filed: July 30, 2001

Title: Novel Human Ion Channel Proteins and
Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0208-USA

Group Art Unit: 1646

Examiner: To Be Assigned

RECEIVED

DEC 1 6 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Box DD
Arlington, VA 22202

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

under 37 CFR 1.97(b), or in the alternative,
(Within three months of filing national application; or date of entry of international
application; or before mailing date of first office action on the merits; whichever
occurs last)

under 37 CFR 1.97(c) together with either a:

Certification under 37 CFR 1.97(e), or
 a \$240.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of
allowance, whichever occurs first)

under 37 CFR 1.97(d) together with a:

Certification under 37 CFR 1.97(e), and
 a petition under 37 CFR 1.97(d)(2)(ii), and
 a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).
(Filed after final action or notice of allowance, whichever occurs first, but before
payment of the issue fee)

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together
with copies, of patents, publications or other information of which applicant(s) are aware, which
applicant(s) believe(s) may be material to the examination of this application and for which there
may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that under 37 CFR § 1.97 (e)(1) each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application not more than three (3) months prior to the filing of this Information Disclosure Statement.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.


Respectfully submitted,

December 11, 2002
Date

Lance K. Ishimoto by David W. Hieber Reg. No. 41,866
Lance K. Ishimoto
Reg. No. 41,866

LEXICON GENETICS INCORPORATED
8800 Technology Forest Place
The Woodlands, TX 77381
(281) 863-3333





Please type a plus sign (+) inside this box → +

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/918,359
		Filing Date	July 30, 2001
		First Named Inventor	Walke
		Group Art Unit	1646
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	6	Attorney Docket Number	LEX-0208-USA

RECEIVED

DEC 16 2002

TECH CENTER 1600/2900

Total Number of Pages in This Submission

6

Attorney Docket Number

LEX-0208-USA

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Change of Correspondence Address	- Return Postcard
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	- Supplemental Form PTO1449 and copies of 6 references cited
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	- International Search Report as Reference CN
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Lexicon Genetics Incorporated		
Signature	Lance K. Ishimoto	Reg. No. 41,866	
Date	December 11, 2002		24231 PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Arlington, VA 22202 on this date: December 11, 2002

Typed or printed name	Michelle Klein	Date	December 11, 2002
Signature			